2014 has been identified as the make-or-break year for electronic health records (EHRs). Despite a more than $22 billion federal investment to reward meaningful use of EHR technology, new report findings suggest that the government has failed to put protections in place that would prevent the technology from increasing costs, including through overbilling.
2014 has been identified as the “make-or-break year” for electronic health records (EHRs). Despite a more than $22 billion federal investment to reward meaningful use of EHR technology, new report findings suggest that the government has failed to put protections in place that would prevent the technology from increasing costs, including through overbilling.
“We’re continuing to see the use of cut-and-paste in health care organizations because clinicians find it is one of the only ways they can manage the documentation process,” said Michelle Dougherty, the senior director of research and development at the American Health Information Management Association, “but there is the potential that there is information being copied that is not relevant or [is] even erroneous.”
As much as EHRs promise to improve care, one study showed that a group of physicians in an emergency department spent nearly half of their shift entering dating, and only about a third of their time engaging with patients.
Dr Ashish K. Jha, professor of health policy at the Harvard School of Public Health, says that longtime supporters of EHRs have “spent a lot of years overhyping and overselling it.”
If EHRs can successfully be integrated into health systems, it could simplify efforts in monitoring patient populations, reduce medical errors, and cultivate innovation. “Big data is really having the ability to track patients through their life cycle and then use smart analytics to understand not just the life cycle of the patient but how it compares to [the] population,” says Jan De Witte, CEO of General Electric’s healthcare IT division.
Paul Black, CEO and president of Allscripts Healthcare Solutions, adds: “Once everything is automated and once everything is digitized, you actually have the promise of really permanently moving the meter on the care that’s delivered and the amount of money that it takes to deliver it.”
Around the Web
Electronic Health Records' ‘Make-or-Break Year’ [Bloomberg]
Report Finds More Flaws in Digitizing Patient Files [The NY Times]
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Researchers Identify Potential Biomarkers for SMA Motor Improvement Following Nusinersen Treatment
November 17th 2023A retrospective, exploratory analysis identifies biomarkers predictive of spinal muscular atrophy (SMA) response to nusinersen and suggests the efficacy of using machine learning algorithms to anticipate patient outcomes.
Read More
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies
November 17th 2023The FDA approved delandistrogene moxeparvovec-rokl (Elevidys, Sarepta Therapeutics) in June to treat Duchenne muscular dystrophy in ambulatory pediatric patients aged 4 through 5 who have a confirmed DMD gene mutation.
Read More